Nivo and the cytotoxic T-lymphocyte antigen-4 (CTLA-4)-specific antibody ipi have different mechanisms of action that contribute to the release of anti-tumor T-cells from checkpoint blockade and to the induction of de novo anti-tumor T-cell responses, respectively [44]. This evidence concerns the gene CTLA4 and neoplasm.